Life Biosciences
About Life Biosciences
Life Biosciences is a biotechnology company focused on aging biology and cellular rejuvenation therapies. The company is developing a partial epigenetic reprogramming platform to reverse and prevent multiple diseases of aging, with the aim of extending healthy human lifespan. They highlight groundbreaking research in aging biology, including connections to Shinya Yamanaka’s Nobel-prize winning work. Life Biosciences operates in the biomedical field, targeting aging-related diseases and aging processes to improve healthspan.
Recent News
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Developing a Drug To Reverse Heart Disease
Life Biosciences Prepares First Human Trial of Partial Cellular Reprogramming for Glaucoma
Remaining Challenges in the Development of Partial Reprogramming Therapies
Longevity Science Picks up Steam in Pharma
This Method to Reverse Cellular Aging Is About to Be Tested in Humans
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
Life Biosciences to Begin First Human Partial Reprogramming Trial in 2026
Partial Reprogramming Concern Altos Labs Is Becoming Less Stealthy
David Sinclair Enters $101 Million XPrize with Oral Rejuvenation Drug
David Sinclair Plans to Test Whole-Body Rejuvenation Drugs in the XPrize Competition